DXR Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -- compared to Daxor Corp.'s net margin of -12425.36%. Daxor Corp.'s return on equity of 1.57% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Daxor Corp. has a consensus price target of $22.00, signalling upside risk potential of 74.74%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 354.16%. Given that Perspective Therapeutics, Inc. has higher upside potential than Daxor Corp., analysts believe Perspective Therapeutics, Inc. is more attractive than Daxor Corp..

Daxor Corp. has a beta of -0.002, which suggesting that the stock is 100.211% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

Daxor Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daxor Corp. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Daxor Corp. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Daxor Corp.'s net income of -- is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Daxor Corp.'s price-to-earnings ratio is 40.36x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daxor Corp. is 58.38x versus 183.75x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Precision Optics Corp., Inc. has a net margin of -- compared to Daxor Corp.'s net margin of -24.5%. Daxor Corp.'s return on equity of 1.57% beat Precision Optics Corp., Inc.'s return on equity of -54.55%.

Daxor Corp. has a consensus price target of $22.00, signalling upside risk potential of 74.74%. On the other hand Precision Optics Corp., Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Daxor Corp. has higher upside potential than Precision Optics Corp., Inc., analysts believe Daxor Corp. is more attractive than Precision Optics Corp., Inc..

Daxor Corp. has a beta of -0.002, which suggesting that the stock is 100.211% less volatile than S&P 500. In comparison Precision Optics Corp., Inc. has a beta of 0.265, suggesting its less volatile than the S&P 500 by 73.5%.

Daxor Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision Optics Corp., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daxor Corp. pays -- of its earnings as a dividend. Precision Optics Corp., Inc. pays out -- of its earnings as a dividend.

Daxor Corp. quarterly revenues are --, which are smaller than Precision Optics Corp., Inc. quarterly revenues of $6.7M. Daxor Corp.'s net income of -- is lower than Precision Optics Corp., Inc.'s net income of -$1.6M. Notably, Daxor Corp.'s price-to-earnings ratio is 40.36x while Precision Optics Corp., Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daxor Corp. is 58.38x versus 1.68x for Precision Optics Corp., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sanara MedTech, Inc. has a net margin of -- compared to Daxor Corp.'s net margin of 3.17%. Daxor Corp.'s return on equity of 1.57% beat Sanara MedTech, Inc.'s return on equity of -20.48%.

Daxor Corp. has a consensus price target of $22.00, signalling upside risk potential of 74.74%. On the other hand Sanara MedTech, Inc. has an analysts' consensus of $40.00 which suggests that it could grow by 83.91%. Given that Sanara MedTech, Inc. has higher upside potential than Daxor Corp., analysts believe Sanara MedTech, Inc. is more attractive than Daxor Corp..

Daxor Corp. has a beta of -0.002, which suggesting that the stock is 100.211% less volatile than S&P 500. In comparison Sanara MedTech, Inc. has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.17%.

Daxor Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanara MedTech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daxor Corp. pays -- of its earnings as a dividend. Sanara MedTech, Inc. pays out -- of its earnings as a dividend.

Daxor Corp. quarterly revenues are --, which are smaller than Sanara MedTech, Inc. quarterly revenues of $26.3M. Daxor Corp.'s net income of -- is lower than Sanara MedTech, Inc.'s net income of $834.5K. Notably, Daxor Corp.'s price-to-earnings ratio is 40.36x while Sanara MedTech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daxor Corp. is 58.38x versus 1.83x for Sanara MedTech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Warby Parker, Inc. has a net margin of -- compared to Daxor Corp.'s net margin of 2.65%. Daxor Corp.'s return on equity of 1.57% beat Warby Parker, Inc.'s return on equity of 0.2%.

Daxor Corp. has a consensus price target of $22.00, signalling upside risk potential of 74.74%. On the other hand Warby Parker, Inc. has an analysts' consensus of $27.25 which suggests that it could grow by 3.3%. Given that Daxor Corp. has higher upside potential than Warby Parker, Inc., analysts believe Daxor Corp. is more attractive than Warby Parker, Inc..

Daxor Corp. has a beta of -0.002, which suggesting that the stock is 100.211% less volatile than S&P 500. In comparison Warby Parker, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Daxor Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Warby Parker, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daxor Corp. pays -- of its earnings as a dividend. Warby Parker, Inc. pays out -- of its earnings as a dividend.

Daxor Corp. quarterly revenues are --, which are smaller than Warby Parker, Inc. quarterly revenues of $221.7M. Daxor Corp.'s net income of -- is lower than Warby Parker, Inc.'s net income of $5.9M. Notably, Daxor Corp.'s price-to-earnings ratio is 40.36x while Warby Parker, Inc.'s PE ratio is 6,942.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daxor Corp. is 58.38x versus 3.83x for Warby Parker, Inc.. Usually stocks with elevated PS ratios are considered overvalued.